Neurocrine Biosciences Initiates P-I Study of NBIP-01435 to Treat CAH

• Neurocrine initiated a P-I first-in-human study of NBIP-01435 to assess safety, PK/PD, tolerability, and immunogenicity in healthy adults via SC injection for the potential treatment of congenital adrenal hyperplasia (CAH)
• NBIP-01435 (CRF1 antagonist) aims to improve androgen control and reduce glucocorticoid dosing. In Dec’24, the FDA approved Neurocrine’s crinecerfont, an oral CRF1 antagonist, to treat CAH in 70yrs
• In April 2021, Neurocrine and Sentia Medical Sciences entered into a research collaboration focused on identifying new peptide CRF receptor antagonists. This collaboration led to the discovery of NBIP-01435, for which Neurocrine has exclusive rights to develop and commercialize

Ref: Prnewswire | Image: Neurocrine Biosciences| Press Release

Related News:- Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington’s Disease Chorea

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com